11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Ictady

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Tenofovirdisoproxil

Tenofovirdisoproxil

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73:199-213.

  2. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31:213-232.

  3. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773-81.

  4. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-7.

  5. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2021. The Antiretroviral Pregnancy Registry [www]. [updated 2021-12-31, cited 2022-03-04].

  6. Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut. 2022;71(4):798-806.

  7. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018;378(10):911-923.

  8. Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019;49(2):211-217.

  1. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. Am J Reprod Immunol. 2015;73:199-213.
  2. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. AIDS. 2017;31:213-232.
  3. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013;57:1773-81.
  4. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502-7.
  5. The Antiretroviral Pregnancy Registry. Interim report 1 January 1989 through 31 July 2021. The Antiretroviral Pregnancy Registry [www]. [updated 2021-12-31, cited 2022-03-04].
  6. Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y et al. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut. 2022;71(4):798-806.
  7. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C et al. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018;378(10):911-923.
  8. Wang M, Bian Q, Zhu Y, Pang Q, Chang L, Li R et al. Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther. 2019;49(2):211-217.